Kazakhstan’s government has approved major investment projects to build four modern pharmaceutical manufacturing plants to expand domestic drug production.
The total investment is estimated at 173 billion tenge (about $340 million). The projects will be implemented by four companies: AltINFARM LLP; Nobel Almaty Pharmaceutical Factory JSC; Abdi Ibrahim Global Pharm LLP; and MSP-Romfarm LLP.
International partnerships
Several of the projects involve international partners. AltINFARM is working with China’s Sinopharm, Sinovac, and Kangtai Biological Technology. Abdi Ibrahim Global Pharm’s partner is Nobel İlaç of Turkey, while MSP-Romfarm is partnering with World Medicine of Turkey and Rompharm of Romania.
According to the government, the projects will localize the production of 356 types of medicines, including essential ones.
Focus on critical medicines
The list of planned products includes treatments for cancer and diabetes, as well as antiviral and immunobiological medicines. The plants will also manufacture analgesics, anti-inflammatory drugs, cold and flu treatments, and antimicrobial medications.
Locations across the country
Two of the pharmaceutical plants will be built in Almaty, with the remaining projects located in the Almaty and Turkestan regions.
